Aptose Biosciences (TSE:APS) Releases Quarterly Earnings Results

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) posted its quarterly earnings data on Tuesday. The biotechnology company reported C($4.07) earnings per share for the quarter, FiscalAI reports.

Aptose Biosciences Stock Up 0.9%

APS traded up C$0.02 on Thursday, hitting C$2.35. 3,904 shares of the company were exchanged, compared to its average volume of 4,228. The firm has a 50-day moving average price of C$2.22 and a two-hundred day moving average price of C$2.06. The company has a current ratio of 0.53, a quick ratio of 5.41 and a debt-to-equity ratio of -97.77. Aptose Biosciences has a twelve month low of C$1.02 and a twelve month high of C$5.80. The company has a market cap of C$6.00 million, a price-to-earnings ratio of 3.41 and a beta of -1.19.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.